CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
On May 11, 2017, Catalyst Biosciences, Inc., a Delaware
corporation (the Company), announced its first quarter 2017
financial results. A copy of the Companys press release is
attached as Exhibit 99.1 hereto and incorporated by reference
herein.
The information concerning financial results in this Form 8-K and
in Exhibit 99.1 shall not be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that section. The
information concerning financial results in this Form 8-K and in
Exhibit 99.1 shall not be incorporated into any registration
statement or other document filed with the Securities and
Exchange Commission by the Company, whether made before or after
the date hereof, regardless of any general incorporation language
in such filing, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press release issued on May 11, 2017 by Catalyst |
About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development. CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Recent Trading Information
CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) closed its last trading session down -0.09 at 4.16 with 199,023 shares trading hands.
